Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 2
1982 1
1983 3
1984 5
1985 15
1986 14
1987 11
1988 5
1989 6
1991 2
1992 2
1993 2
1994 1
1995 2
1996 5
1997 5
1998 5
1999 5
2000 1
2001 1
2002 4
2003 4
2004 3
2005 4
2006 4
2007 3
2008 4
2009 6
2010 2
2011 3
2012 5
2013 5
2014 4
2015 4
2016 6
2017 5
2018 2
2019 8
2020 3
2021 6
2022 12
2023 11
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

192 results

Results by year

Filters applied: . Clear all
Page 1
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA; RUBY Investigators. Mirza MR, et al. Among authors: copeland lj. N Engl J Med. 2023 Jun 8;388(23):2145-2158. doi: 10.1056/NEJMoa2216334. Epub 2023 Mar 27. N Engl J Med. 2023. PMID: 36972026 Clinical Trial.
In Reply.
Chan JK, Tian C, Kesterson JP, Monk BJ, Kapp DS, Davidson B, Robertson S, Copeland LJ, Walker JL, Wenham R, Casablanca Y, Spirtos NM, Tewari KS, Bell JG. Chan JK, et al. Among authors: copeland lj. Obstet Gynecol. 2022 Jun 1;139(6):1196-1197. doi: 10.1097/AOG.0000000000004817. Obstet Gynecol. 2022. PMID: 35675622 No abstract available.
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).
Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ. Tewari KS, et al. Among authors: copeland lj. Lancet. 2017 Oct 7;390(10103):1654-1663. doi: 10.1016/S0140-6736(17)31607-0. Epub 2017 Jul 27. Lancet. 2017. PMID: 28756902 Free PMC article. Clinical Trial.
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, Fowler JM, Greer BE, Boente M, Liang SX, Ye C, Bais C, Randall LM, Chan JK, Ferriss JS, Coleman RL, Aghajanian C, Herzog TJ, DiSaia PJ, Copeland LJ, Mannel RS, Birrer MJ, Monk BJ. Tewari KS, et al. Among authors: copeland lj. J Clin Oncol. 2019 Sep 10;37(26):2317-2328. doi: 10.1200/JCO.19.01009. Epub 2019 Jun 19. J Clin Oncol. 2019. PMID: 31216226 Free PMC article. Clinical Trial.
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
You B, Purdy C, Copeland LJ, Swisher EM, Bookman MA, Fleming G, Coleman R, Randall LM, Tewari KS, Monk BJ, Mannel RS, Walker JL, Cappuccini F, Cohn D, Muzaffar M, Mutch D, Wahner-Hendrickson A, Martin L, Colomban O, Burger RA. You B, et al. Among authors: copeland lj. J Clin Oncol. 2022 Dec 1;40(34):3965-3974. doi: 10.1200/JCO.22.01207. Epub 2022 Oct 17. J Clin Oncol. 2022. PMID: 36252167 Free PMC article. Clinical Trial.
Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial.
Powell MA, Filiaci VL, Hensley ML, Huang HQ, Moore KN, Tewari KS, Copeland LJ, Secord AA, Mutch DG, Santin A, Warshal DP, Spirtos NM, DiSilvestro PA, Ioffe OB, Miller DS. Powell MA, et al. Among authors: copeland lj. J Clin Oncol. 2022 Mar 20;40(9):968-977. doi: 10.1200/JCO.21.02050. Epub 2022 Jan 10. J Clin Oncol. 2022. PMID: 35007153 Free PMC article. Clinical Trial.
Practice changing cervical cancer clinical trials.
Pothuri B, Eskander RN, Randall LM, O'Malley DM, Slomovitz B, Moore KN, Herzog TJ, Coleman RL, Copeland LJ, Monk BJ. Pothuri B, et al. Among authors: copeland lj. Gynecol Oncol. 2022 Jun;165(3):410-412. doi: 10.1016/j.ygyno.2022.03.004. Epub 2022 Apr 20. Gynecol Oncol. 2022. PMID: 35461731 No abstract available.
Ovarian cancer. Foreword.
van Nagell JR Jr, Copeland LJ. van Nagell JR Jr, et al. Among authors: copeland lj. Clin Obstet Gynecol. 2012 Mar;55(1):1-2. doi: 10.1097/GRF.0b013e31824c686b. Clin Obstet Gynecol. 2012. PMID: 22343224 No abstract available.
Joint ENGOT and GOG Foundation requirements for trials with industry partners.
Vergote I, Coleman RL, Pignata S, Bookman MA, Marth C, Herzog TJ, Gonzalez-Martin A, Copeland LJ; European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation Inc.. Vergote I, et al. Among authors: copeland lj. Gynecol Oncol. 2019 Aug;154(2):255-258. doi: 10.1016/j.ygyno.2019.04.677. Gynecol Oncol. 2019. PMID: 31331494 No abstract available.
192 results